JUPITER NEUROSCIENCES, INC.(JUNS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
JUNS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for JUPITER NEUROSCIENCES, INC. (JUNS), a Healthcare sector company. JUNS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), JUPITER NEUROSCIENCES, INC. reports quarterly revenue of $18.7K, net income of $-2.1M, free cash flow of $-1.4M. Top institutional holders of JUNS by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, Yorkville Advisors Global,, based on the most recent SEC filings. JUNS trades on the Nasdaq exchange and files with the SEC under CIK 1679628. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JUNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for JUPITER NEUROSCIENCES, INC. directly from SEC EDGAR.
Revenue
Q1 2026
$18.7K
Net Income
Q1 2026
$-2.1M
Free Cash Flow
Q1 2026
$-1.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+49.0% YoYOperating Income
+20.1% YoYEPS (Diluted)
+55.6% YoYTotal Assets
+4074.1% YoYOp. Cash Flow
-713.2% YoY| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $0.00 | — |
| Net Income | $-2.4M +49.0% | $-4.8M |
| Operating Income | $-3.1M +20.1% | $-3.9M |
| EPS (Diluted) | $-0.08 +55.6% | $-0.18 |
| Total Assets | $6.2M +4074.1% | $148.6K |
| Operating Cash Flow | $-3.9M -713.2% | $-481.0K |
AI Insight: JUNS Financial Trends
JUNS is burning cash with no revenue while equity deteriorates toward insolvency.
• Operating cash burn steady at $1–2M quarterly; Q4 2025 peaked at $2M, latest quarter $1M.
• Equity collapsed from $4M (Q4 2024) to negative $3M (Q1 2026), signaling shareholder value erosion.
• No revenue recorded across all periods; net losses consistent at $2–3M per quarter.
⚠ Negative equity position since Q3 2025 — technical insolvency. Capital raise or asset sale imminent.
⚠ Sustained operating losses with zero revenue suggest pre-commercial or discontinued operations.
AI Insight: JUNS Ratio Trends
Insufficient financial data to establish meaningful trends; only two quarters show results, both deeply negative.
• Q4 2024 and Q1 2025 show severe losses: ROE of −146.5% and −199.6%, ROA of −98.5%. No profitability metrics available thereafter.
⚠ Eight of nine rows lack OpMargin, NPM, ROIC, and D/E data. Cannot assess margin trajectory, leverage, or capital efficiency.
⚠ Earliest available results (Q4 2024–Q1 2025) show acute losses. Path to profitability and turnaround timing remain opaque.
Get alerted when JUNS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for JUPITER NEUROSCIENCES, INC. including:
Top Institutional Holders of JUNS
VANGUARD CAPITAL MANAGEMENT LLC
$135.3K359,911 shGEODE CAPITAL MANAGEMENT, LLC
$79.6K211,696 shYorkville Advisors Global, LP
$48.5K129,000 shCITADEL ADVISORS LLC
$38.2K101,661 shVANGUARD FIDUCIARY TRUST CO
$33.0K87,789 shNORTHERN TRUST CORP
$9.5K25,346 shUBS Group AG
$1.5K3,928 shMidFirst Bank
$376.001,000 shVESTOR CAPITAL, LLC
$365.00970,985 shVirtu Financial LLC
$5.0013,575 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $135.3K | 359,911 |
| GEODE CAPITAL MANAGEMENT, LLC | $79.6K | 211,696 |
| Yorkville Advisors Global, LP | $48.5K | 129,000 |
| CITADEL ADVISORS LLC | $38.2K | 101,661 |
| VANGUARD FIDUCIARY TRUST CO | $33.0K | 87,789 |
| NORTHERN TRUST CORP | $9.5K | 25,346 |
| UBS Group AG | $1.5K | 3,928 |
| MidFirst Bank | $376.00 | 1,000 |
| VESTOR CAPITAL, LLC | $365.00 | 970,985 |
| Virtu Financial LLC | $5.00 | 13,575 |
More Healthcare Companies
View all Healthcare →Put JUNS on your watchlist
Track score changes the day JUPITER NEUROSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is JUNS a good stock to buy?
13F Pro's AI-powered analysis of JUPITER NEUROSCIENCES, INC. (JUNS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JUNS are available on the JUNS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own JUNS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JUNS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of JUPITER NEUROSCIENCES, INC.'s investment landscape.